Acceleron Pharma Inc (NASDAQ:XLRN) EVP Matthew L. Sherman sold 4,633 shares of Acceleron Pharma stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $42.71, for a total transaction of $197,875.43. Following the sale, the executive vice president now directly owns 77,700 shares in the company, valued at approximately $3,318,567. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Acceleron Pharma Inc (NASDAQ XLRN) traded down $1.46 during trading hours on Thursday, reaching $42.94. 332,656 shares of the company traded hands, compared to its average volume of 275,733. Acceleron Pharma Inc has a 1-year low of $23.07 and a 1-year high of $44.80. The company has a market capitalization of $1,929.73, a price-to-earnings ratio of -16.58 and a beta of 1.59.

Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.02. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.55) earnings per share. analysts expect that Acceleron Pharma Inc will post -2.65 EPS for the current year.

A number of equities research analysts have recently weighed in on XLRN shares. Credit Suisse Group set a $51.00 target price on shares of Acceleron Pharma and gave the company a “buy” rating in a research note on Tuesday, November 14th. HC Wainwright started coverage on shares of Acceleron Pharma in a research note on Thursday, October 12th. They set a “buy” rating and a $57.00 target price on the stock. Royal Bank of Canada reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Thursday, November 2nd. Barclays lifted their target price on shares of Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, September 20th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, November 14th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $44.56.

A number of institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP purchased a new position in Acceleron Pharma in the third quarter worth about $1,496,000. Iguana Healthcare Management LLC purchased a new position in Acceleron Pharma in the third quarter worth about $2,612,000. Point72 Asset Management L.P. purchased a new position in Acceleron Pharma in the third quarter worth about $2,721,000. Granahan Investment Management Inc. MA raised its holdings in Acceleron Pharma by 15.2% in the third quarter. Granahan Investment Management Inc. MA now owns 217,091 shares of the biopharmaceutical company’s stock worth $8,102,000 after buying an additional 28,694 shares during the last quarter. Finally, Perceptive Advisors LLC raised its holdings in Acceleron Pharma by 127.2% in the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock worth $60,319,000 after buying an additional 905,000 shares during the last quarter. 85.70% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Acceleron Pharma Inc (XLRN) EVP Sells 4,633 Shares of Stock” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/04/insider-selling-acceleron-pharma-inc-xlrn-evp-sells-4633-shares-of-stock.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.